These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31784598)

  • 1. Effect of tumor necrosis factor inhibition on spinal inflammation and spinal ankylosis in SKG mice.
    Lim DH; Lee EJ; Kwon OC; Hong S; Lee CK; Yoo B; Youn J; Kim TH; Kim YG
    Sci Rep; 2019 Nov; 9(1):18000. PubMed ID: 31784598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of dihydrotestosterone on osteoblast activity in curdlan-administered SKG mice and osteoprogenitor cells in patients with ankylosing spondylitis.
    Jo S; Lee EJ; Nam B; Kang J; Lee S; Youn J; Park YS; Kim YG; Kim TH
    Arthritis Res Ther; 2020 May; 22(1):121. PubMed ID: 32448352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rebamipide prevents peripheral arthritis and intestinal inflammation by reciprocally regulating Th17/Treg cell imbalance in mice with curdlan-induced spondyloarthritis.
    Min HK; Kim JK; Lee SY; Kim EK; Lee SH; Lee J; Kwok SK; Cho ML; Park SH
    J Transl Med; 2016 Jun; 14(1):190. PubMed ID: 27350608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural progression rate decreases over time on serial radiography and magnetic resonance imaging of sacroiliac joints and spine in a five-year follow-up study of patients with ankylosing spondylitis treated with tumour necrosis factor inhibitor.
    Pedersen SJ; Weber U; Said-Nahal R; Sørensen IJ; Loft AG; Kollerup G; Juul L; Frandsen PB; Thamsborg G; Madsen OR; Møller J; Balding L; Jurik AG; Østergaard M
    Scand J Rheumatol; 2019 May; 48(3):185-197. PubMed ID: 30422733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-glucan triggers spondylarthritis and Crohn's disease-like ileitis in SKG mice.
    Ruutu M; Thomas G; Steck R; Degli-Esposti MA; Zinkernagel MS; Alexander K; Velasco J; Strutton G; Tran A; Benham H; Rehaume L; Wilson RJ; Kikly K; Davies J; Pettit AR; Brown MA; McGuckin MA; Thomas R
    Arthritis Rheum; 2012 Jul; 64(7):2211-22. PubMed ID: 22328069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-body Magnetic Resonance Imaging in Axial Spondyloarthritis: Reduction of Sacroiliac, Spinal, and Entheseal Inflammation in a Placebo-controlled Trial of Adalimumab.
    Krabbe S; Østergaard M; Eshed I; Sørensen IJ; Jensen B; Møller JM; Balding L; Madsen OR; Asmussen K; Eng G; Jørgensen NR; Pedersen SJ
    J Rheumatol; 2018 May; 45(5):621-629. PubMed ID: 29449506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Swimming exercise alleviates pathological bone features in curdlan-injected SKG mice by inducing irisin expression.
    Lee SH; Nam B; Youn J; Lee KH; Jo S
    Life Sci; 2024 Sep; 352():122894. PubMed ID: 38971365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spondyloarthritis features in zymosan-induced SKG mice.
    Jeong H; Bae EK; Kim H; Lim DH; Chung TY; Lee J; Jeon CH; Koh EM; Cha HS
    Joint Bone Spine; 2018 Oct; 85(5):583-591. PubMed ID: 29197633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STAT3 phosphorylation inhibition for treating inflammation and new bone formation in ankylosing spondylitis.
    Jo S; Won EJ; Kim MJ; Lee YJ; Jin SH; Park PR; Song HC; Kim J; Choi YD; Kim JY; Shim SC; Choi SH; Park YS; Kim TH; Kim TJ
    Rheumatology (Oxford); 2021 Aug; 60(8):3923-3935. PubMed ID: 33237331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of spinal bone formation in AS: 10 years after comparing adalimumab to OASIS.
    van der Heijde D; Landewé R
    Arthritis Res Ther; 2019 Nov; 21(1):225. PubMed ID: 31694713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vertebral erosions associated with spinal inflammation in patients with ankylosing spondylitis identified by magnetic resonance imaging: changes after 2 years of tumor necrosis factor inhibitor therapy.
    Baraliakos X; Listing J; Haibel H; Sieper J; Braun J
    J Rheumatol; 2013 Nov; 40(11):1891-6. PubMed ID: 23908444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Lambert RG; Salonen D; Rahman P; Inman RD; Wong RL; Einstein SG; Thomson GT; Beaulieu A; Choquette D; Maksymowych WP
    Arthritis Rheum; 2007 Dec; 56(12):4005-14. PubMed ID: 18050198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic association of ankylosing spondylitis with TBX21 influences T-bet and pro-inflammatory cytokine expression in humans and SKG mice as a model of spondyloarthritis.
    Lau MC; Keith P; Costello ME; Bradbury LA; Hollis KA; Thomas R; Thomas GP; Brown MA; Kenna TJ
    Ann Rheum Dis; 2017 Jan; 76(1):261-269. PubMed ID: 27125523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years.
    Poddubnyy D; Fedorova A; Listing J; Haibel H; Baraliakos X; Braun J; Sieper J
    J Rheumatol; 2016 Dec; 43(12):2142-2148. PubMed ID: 27803139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial.
    Haibel H; Rudwaleit M; Brandt HC; Grozdanovic Z; Listing J; Kupper H; Braun J; Sieper J
    Arthritis Rheum; 2006 Feb; 54(2):678-81. PubMed ID: 16447247
    [No Abstract]   [Full Text] [Related]  

  • 16. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort.
    Molnar C; Scherer A; Baraliakos X; de Hooge M; Micheroli R; Exer P; Kissling RO; Tamborrini G; Wildi LM; Nissen MJ; Zufferey P; Bernhard J; Weber U; Landewé RBM; van der Heijde D; Ciurea A;
    Ann Rheum Dis; 2018 Jan; 77(1):63-69. PubMed ID: 28939631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spondyloarthropathies: ankylosing spondylitis and psoriatic arthritis.
    Bennett DL; Ohashi K; El-Khoury GY
    Radiol Clin North Am; 2004 Jan; 42(1):121-34. PubMed ID: 15049527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis.
    Hu Z; Xu M; Li Q; Lin Z; Liao Z; Cao S; Wei Q; Zhang YL; Li T; Jin O; Huang J; Pan Y; Wu Y; Deng X; Gu J
    Int J Rheum Dis; 2012 Aug; 15(4):358-65. PubMed ID: 22898215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.
    van der Heijde D; Breban M; Halter D; DiVittorio G; Bratt J; Cantini F; Kary S; Pangan AL; Kupper H; Rathmann SS; Sieper J; Mease PJ
    Rheumatology (Oxford); 2015 Jul; 54(7):1210-9. PubMed ID: 25541333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.